Julie A Kish
Overview
Explore the profile of Julie A Kish including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
1951
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Strom T, Naghavi A, Trotti A, Russell J, Kish J, McCaffrey J, et al.
J Geriatr Oncol
. 2016 Oct;
8(1):50-55.
PMID: 27720129
Purpose: Concurrent chemoradiotherapy (CRT) is the standard of care for many sites of locally advanced head and neck squamous cell carcinomas (LAHNC). However, on meta-analysis, the addition of chemotherapy did...
12.
Frakes J, Naghavi A, Demetriou S, Strom T, Russell J, Kish J, et al.
Cancer
. 2015 Nov;
122(4):634-41.
PMID: 26565997
Background: Determining the optimal follow-up for patients can help maximize the use of health care resources. This is particularly true in a growing epidemic such as human papillomavirus-positive oropharyngeal squamous...
13.
Rao N, Han G, Greene J, Tanvetyanon T, Kish J, De Conti R, et al.
Pract Radiat Oncol
. 2014 Mar;
3(3):229-233.
PMID: 24674369
Purpose: Radiation therapy (RT) or chemoradiation therapy (CRT) for carcinoma of the head and neck can result in high rates of candidiasis and mucositis. Prophylactic fluconazole (FCZ) has been shown...
14.
Tanvetyanon T, Padhya T, McCaffrey J, Kish J, DeConti R, Trotti A, et al.
Head Neck
. 2014 Mar;
37(6):840-5.
PMID: 24623654
Background: Despite resection followed by adjuvant radiotherapy, high-risk cutaneous squamous cell carcinomas of the head and neck region (SCCHN) often recur. Because adjuvant concurrent chemoradiation reduces recurrence among high-risk mucosal...
15.
Gray J, Haura E, Chiappori A, Tanvetyanon T, Williams C, Pinder-Schenck M, et al.
Clin Cancer Res
. 2014 Jan;
20(6):1644-55.
PMID: 24429877
Purpose: Panobinostat, a histone deacetylase (HDAC) inhibitor, enhances antiproliferative activity in non-small cell lung cancer (NSCLC) cell lines when combined with erlotinib. We evaluated this combination in patients with advanced...
16.
Cooper J, Zhang Q, Pajak T, Forastiere A, Jacobs J, Saxman S, et al.
Int J Radiat Oncol Biol Phys
. 2012 Jul;
84(5):1198-205.
PMID: 22749632
Purpose: Previous analysis of this Intergroup trial demonstrated that with a median follow-up among surviving patients of 45.9 months, the concurrent postoperative administration of cisplatin and radiation therapy improved local-regional...
17.
Swinnen L, Rankin C, Carraway H, Albain K, Townsend J, Budd G, et al.
J Neurooncol
. 2008 Jan;
86(3):353-8.
PMID: 18175205
Inhibition of DNA excision repair can modulate resistance to cisplatin. Cytosine arabinoside (Ara-C) and hydroxyurea (HU), in combination, inhibit the excision-repair system and removal of platinum-DNA adducts. Marked cytotoxic synergy...
18.
Cooper J, Pajak T, Forastiere A, Jacobs J, Campbell B, Saxman S, et al.
N Engl J Med
. 2004 May;
350(19):1937-44.
PMID: 15128893
Background: Despite the use of resection and postoperative radiotherapy, high-risk squamous-cell carcinoma of the head and neck frequently recurs in the original tumor bed. We tested the hypothesis that concurrent...
19.
Adelstein D, Li Y, Adams G, Wagner Jr H, Kish J, Ensley J, et al.
J Clin Oncol
. 2002 Dec;
21(1):92-8.
PMID: 12506176
Purpose: The Head and Neck Intergroup conducted a phase III randomized trial to test the benefit of adding chemotherapy to radiation in patients with unresectable squamous cell head and neck...